+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07818018

Intratumoral CD40 Agonist 2141-V11 Combined with Anti-PD-1 and 5-Fluorouracil Therapy for Advanced Gastroesophageal Adenocarcinoma

Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-09-14

30

Participants Needed

7

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying whether adding the drug 2141-V11 to standard treatment, which includes anti-PD-1 immunotherapy with or without 5-fluorouracil 5-FU, is a safe approach for people with advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma. This study involves participants who have locally advanced unresectable or metastatic disease and are on first-line systemic therapy. The trial is divided into Phase 1b and Phase II components, focusing on safety and potential treatment effects. The study treatments include intratumoral injections of 2141-V11, a monoclonal antibody targeting the CD40 receptor, combined with intravenous nivolumab an anti-PD-1 antibody and a continuous 48-hour infusion of 5-FU. Initially, a lead-in cohort assesses safety by monitoring dose-limiting toxicities DLTs in the first patients if safe, the study progresses to an expansion cohort in Phase II. Dose adjustments may occur based on observed toxicities, with careful monitoring throughout. Participants undergo regular evaluations including endoscopy to confirm tumor visibility and imaging to assess disease status. Blood tests monitor organ function and safety. The main outcome is to evaluate the safety of 2141-V11 over six weeks. The trial spans from screening through treatment and ongoing monitoring, with participation lasting up to the studys completion in 2029. Researchers track adverse events, treatment tolerability, and disease progression during this time.

CONDITIONS

Brief Title

A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma

Research Team

S

Samuel Cytryn, MD

S

Seung Eun Lee, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here